First Dosing to Patients in ‘Pexa-vec’ Australian Phase 2 Prostate Cancer Clinical Trial
First Dosing to Patients in ‘Pexa-vec’ Australian Phase 2 Prostate Cancer Clinical Trial
  • Cho Pil Hyun, Staff Reporter
  • 승인 2023.06.01 22:00
  • 수정 2023.06.01 22:00
  • 댓글 0
이 기사를 공유합니다

Sillajen. “Patient safety and efficacy to be confirmed”

Sillajen announced on June 1 that it has completed dosing the first patient cohort in an ongoing clinical trial of its oncolytic viral therapy ‘Pexa-vec’ in prostate cancer in Australia.

According to the company, a clinical trial of ‘the Neoadjuvant Study of Intratumoral and Intravenous Pexastimogene Devacirepvec (Pexa-Vec) in Prostate Cancer Prior to Radical Prostatectomy is in progress with the Royal Melbourne Hospital in Australia.

Recently, the first dosing to patients has been completed.

The clinical trial is conducted in three cohorts, all of which will receive the same dose of 1x109 PFU of Pexa-vec. However, 10 subjects in each cohort will be enrolled with different dosing schedules and administration methods, totaling 30 subjects.

Cohort 1 patients will receive a single dose of Pexa-vec to the prostate using an MRI guided injection at least 4 weeks prior to radical prostatectomy.

Cohort 2 patients will receive two MRI-guided doses of Pexa-vec to the prostate 2 weeks apart, and those in Cohort 3 will receive two intravenous doses 1 week apart.

An official from Sillajen said, "The purpose of this clinical trial is to determine if Pexa-vec is a safe and useful treatment for patients with prostate cancer as a preoperative therapy. We hope that Pexa-vec preoperative therapy can improve the prognosis of patients with prostate cancer."

[WIKI KOREA=Cho Pil Hyun, Staff Reporter]

  • 서울특별시 마포구 마포대로 127, 1001호 (공덕동, 풍림빌딩)
  • 대표전화 : 02-702-2677
  • 팩스 : 02-702-1677
  • 청소년보호책임자 : 소정원
  • 법인명 : 위키리크스한국 주식회사
  • 제호 : 위키리크스한국
  • 등록번호 : 서울 아 04701
  • 등록일 : 2013-07-18
  • 발행일 : 2013-07-18
  • 발행인 : 박정규
  • 편집인 : 박찬흥
  • 위키리크스한국은 자체 기사윤리 심의 전문위원제를 운영합니다.
  • 기사윤리 심의 : 박지훈 변호사
  • 위키리크스한국 모든 콘텐츠(영상,기사, 사진)는 저작권법의 보호를 받은바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2023 위키리크스한국. All rights reserved.
  • [위키리크스한국 보도원칙] 본 매체는 독자와 취재원 등 뉴스 이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고 있음을 알립니다.
    고충처리 : 02-702-2677 | 메일 :